OBD vs. TRX, FUM, COS, C4XD, DDDD, OKYO, AOR, AREC, OPTI, and SAR
Should you be buying Oxford BioDynamics stock or one of its competitors? The main competitors of Oxford BioDynamics include Tissue Regenix Group (TRX), Futura Medical (FUM), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), OKYO Pharma (OKYO), AorTech International (AOR), Arecor Therapeutics (AREC), OptiBiotix Health (OPTI), and Sareum (SAR). These companies are all part of the "biotechnology" industry.
Oxford BioDynamics vs.
Tissue Regenix Group (LON:TRX) and Oxford BioDynamics (LON:OBD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk.
Tissue Regenix Group has higher revenue and earnings than Oxford BioDynamics. Tissue Regenix Group is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.
Tissue Regenix Group has a net margin of -3.46% compared to Oxford BioDynamics' net margin of -1,800.32%. Tissue Regenix Group's return on equity of -2.87% beat Oxford BioDynamics' return on equity.
Tissue Regenix Group received 58 more outperform votes than Oxford BioDynamics when rated by MarketBeat users. Likewise, 69.53% of users gave Tissue Regenix Group an outperform vote while only 60.47% of users gave Oxford BioDynamics an outperform vote.
In the previous week, Tissue Regenix Group's average media sentiment score of 0.00 equaled Oxford BioDynamics'average media sentiment score.
Tissue Regenix Group has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Oxford BioDynamics has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.
37.0% of Tissue Regenix Group shares are held by institutional investors. Comparatively, 44.3% of Oxford BioDynamics shares are held by institutional investors. 47.3% of Tissue Regenix Group shares are held by insiders. Comparatively, 16.8% of Oxford BioDynamics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Tissue Regenix Group beats Oxford BioDynamics on 10 of the 13 factors compared between the two stocks.
Get Oxford BioDynamics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oxford BioDynamics Competitors List
Related Companies and Tools
This page (LON:OBD) was last updated on 3/31/2025 by MarketBeat.com Staff
